The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Broadening the gates: Analysis of potentially modifiable screen failures in pancreatic and biliary tract cancer trials.
 
Fen Saj
No Relationships to Disclose
 
Felicity Namayanja
No Relationships to Disclose
 
Mitesh Borad
No Relationships to Disclose
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); GlaxoSmithKline; J-Pharma; Jazz Pharmaceuticals; Kinnate Biopharma; Merck (Inst); Moderna Therapeutics; Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Merck
 
Lipika Goyal
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Cogent Biosciences; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Incyte; Kinnate Biopharma; Merck; QED Therapeutics; SERVIER; Sirtex Medical; Surface Oncology; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
Research Funding - Alyssum (Inst); Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Nilofer Azad
Stock and Other Ownership Interests - Cage Pharma; Irazu; Tempus
Consulting or Advisory Role - Agenus; Astellas Pharma; AstraZeneca; BeiGene; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Melinda Bachini
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Relay Therapeutics
(OPTIONAL) Uncompensated Relationships - ECOG-ACRIN; NCCN; NCI
 
Stacie Lindsey
No Relationships to Disclose
 
Juan Valle
Consulting or Advisory Role - AstraZeneca; Cogent Biosciences (Inst); Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals (Inst); Oncosil (Inst); Owkin (Inst); Redx Pharma (Inst); SERVIER; Taiho Oncology
 
Lola Fashoyin-Aje
No Relationships to Disclose
 
Milind Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen